ATE185487T1 - Verfahren zur hemmung der viralen morphogenese - Google Patents

Verfahren zur hemmung der viralen morphogenese

Info

Publication number
ATE185487T1
ATE185487T1 AT93914329T AT93914329T ATE185487T1 AT E185487 T1 ATE185487 T1 AT E185487T1 AT 93914329 T AT93914329 T AT 93914329T AT 93914329 T AT93914329 T AT 93914329T AT E185487 T1 ATE185487 T1 AT E185487T1
Authority
AT
Austria
Prior art keywords
inhibiting viral
inhibiting
viral morphogenesis
morphogenesis
viral
Prior art date
Application number
AT93914329T
Other languages
English (en)
Inventor
Jeffrey S Glenn
Original Assignee
Jeffrey S Glenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeffrey S Glenn filed Critical Jeffrey S Glenn
Application granted granted Critical
Publication of ATE185487T1 publication Critical patent/ATE185487T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT93914329T 1992-05-29 1993-06-01 Verfahren zur hemmung der viralen morphogenese ATE185487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/890,754 US5503973A (en) 1992-05-29 1992-05-29 Method for inhibition of viral morphogenesis

Publications (1)

Publication Number Publication Date
ATE185487T1 true ATE185487T1 (de) 1999-10-15

Family

ID=25397107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914329T ATE185487T1 (de) 1992-05-29 1993-06-01 Verfahren zur hemmung der viralen morphogenese

Country Status (11)

Country Link
US (3) US5503973A (de)
EP (1) EP0672192B1 (de)
JP (2) JPH08502162A (de)
AT (1) ATE185487T1 (de)
AU (1) AU673841B2 (de)
CA (1) CA2136958C (de)
DE (1) DE69326777T2 (de)
DK (1) DK0672192T3 (de)
ES (1) ES2139660T3 (de)
GR (1) GR3032237T3 (de)
WO (1) WO1993024660A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
WO1997031641A1 (en) * 1996-02-29 1997-09-04 Duke University Method of treating hepatitis delta virus infection
EP0910385A4 (de) * 1996-04-15 1999-12-22 Univ Pennsylvania Sensibilisierung von zellen zur strahlen- und chemotherapie
EP0952834A2 (de) * 1996-05-15 1999-11-03 The University of Sheffield Isopentylpyrophosphate isomere (ipi) und/oder prenyltransferase hemmern
JP5042528B2 (ja) * 2003-02-12 2012-10-03 中外製薬株式会社 ウイルス治療薬
CN100502853C (zh) * 2003-02-12 2009-06-24 中外制药株式会社 抗病毒药
MY141506A (en) * 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug
CA2522089A1 (en) * 2003-04-30 2004-11-11 Consejo Superior De Investigaciones Cientificas Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
BRPI0412459A (pt) 2003-07-09 2006-10-17 Chugai Pharmaceutical Co Ltd composto tendo ação anti-hcv e seu método de produção
AU2005247298B8 (en) 2004-04-14 2011-03-10 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US6627610B1 (en) * 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5941868A (en) * 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US6015877A (en) * 1996-03-14 2000-01-18 President And Fellows Of Harvard College Compounds for inhibition of proteolysis
JP2002509428A (ja) * 1996-08-07 2002-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ａｆｃ１およびｒｃｅ１：イソプレニル化されたｃａａｘプロセシング酵素
DE69838843D1 (de) * 1997-06-11 2008-01-24 Univ New York Prenylcystein carboxyl methyl-transferase, dns, welche für selbige kodiert, und ein verfahren zur suche nach hemmstoffen
SE9703226D0 (sv) * 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) * 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction

Also Published As

Publication number Publication date
DE69326777T2 (de) 2000-03-09
US5876920A (en) 1999-03-02
GR3032237T3 (en) 2000-04-27
JP2005124577A (ja) 2005-05-19
AU673841B2 (en) 1996-11-28
EP0672192A4 (de) 1996-04-17
JP4286764B2 (ja) 2009-07-01
JPH08502162A (ja) 1996-03-12
AU4403293A (en) 1993-12-30
EP0672192A1 (de) 1995-09-20
EP0672192B1 (de) 1999-10-13
WO1993024660A1 (en) 1993-12-09
ES2139660T3 (es) 2000-02-16
CA2136958A1 (en) 1993-12-09
US5503973A (en) 1996-04-02
DK0672192T3 (da) 1999-12-27
CA2136958C (en) 2011-03-22
US20080214471A1 (en) 2008-09-04
DE69326777D1 (de) 1999-11-18

Similar Documents

Publication Publication Date Title
DE69317015D1 (de) Adaptives Signalerkennungsverfahren zur Auswertung von Mehrfrequenz-Kodezeichen-Signalen
DE69329300D1 (de) Verfahren zur Spaltung von Cumolhydroperoxid
DE59310377D1 (de) Verfahren zur Nachprüfung von Sicherheitsabdrucken
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69329461D1 (de) Verfahren zur extraktion und reinigung von hamoglobin
DE59408901D1 (de) Verfahren zur Herstellung von Polyacetalen
DE69119610D1 (de) Verfahren zur mikro-einkapselung von hyperbarem gas
DE3674365D1 (de) Verfahren zur pumpgrenzregelung von turbokompressoren.
DE69326777D1 (de) Verfahren zur hemmung der viralen morphogenese
DE3886710D1 (de) Verfahren zur selektiven inhibierung von hiv.
DE69303621D1 (de) Verfahren zur verbesserung der bioverfuegbarkeit von beta-carotine durch addition von kalzium und kohlenhydraten
DE69204691D1 (de) Verfahren zur Karbonylierung von Olefin.
DE59204440D1 (de) Verfahren zur Erkennung von Verbrennungsaussetzern.
ATE176399T1 (de) Verfahren zur inaktivierung von spermien
DE3684774D1 (de) Verfahren zur hemmung der polymerisierung von maleimiden.
DE69202962D1 (de) Verfahren zur Glycidylierung von Alkoholen.
DE68921870D1 (de) Verfahren zur Reduktion von Stickoxiden.
DE59404520D1 (de) Verfahren zur Hydroformylierung von Butadien-1.3
DE68910188D1 (de) Verfahren zur Standardisierung von Spektrallinien.
DE69016879D1 (de) Verfahren zur Reinigung von N-Phosphonmethylglyzin.
DE68913581D1 (de) Verfahren zur Erkennung der Kontur eines Strahlenfelds.
DE69411333D1 (de) Verfahren zur Rückgewinnung von verbrauchten Metallätzlösungen
DE69415837D1 (de) Verfahren zur Verminderung des freien Aldehydgehaltes von N-Alkylolamidmonomeren
DE3872632D1 (de) Vorrichtung zur diebstahlsicherung von autostereoanlagen.
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee